Alternatives to PAIN Act

WHAT HAPPENED: On February 12, 2025, Rep. Miller-Meeks (R-IA) introduced HR1227, the Alternatives to PAIN Act. The bill amends Medicare Part D (Section 1860D-2 of the Social Security Act) to require that qualifying non-opioid pain management drugs be covered without a deductible, placed on the lowest cost-sharing tier, and that plans cannot impose prior authorization or step therapy on these drugs. The bill's effective date is January 1, 2026. It has 88 cosponsors and has been referred to both the House Energy & Commerce and Ways & Means Committees. There have been zero further actions since referral — no hearings, markup, or floor votes. A companion bill (S475) exists in the Senate, also in early stage.

THE MONEY TRAIL: This bill authorizes zero dollars — it is a regulatory mandate, not an appropriations measure. It imposes new coverage requirements on Medicare Part D plans without providing additional federal funding, subsidies, or risk corridor payments to offset plan liability. Plans would bear the full incremental cost of increased utilization and elimination of cost-sharing until beneficiaries reach the catastrophic threshold. Actual federal budget impact would flow indirectly through Medicare Part D's premium and reinsurance mechanisms, but no CBO score has been published.

STRUCTURAL WINNERS AND LOSERS: The only structural beneficiaries are manufacturers of qualifying non-opioid pain drugs — drugs that have an FDA-approved indication for acute pain, do not act on opioid receptors, have no therapeutically equivalent generic, and meet the WAC definition. Currently, potential candidates include branded non-opioid injectables like Exparel (Pacira, $PCRX), Zynrelef (Heron, $HRTX), and Anjeso (Eagle, $EGRX). However, these tickers were not included because the bill's language requires the drug to have 'no other drug or product that is rated as therapeutically equivalent' and explicitly references the FDA's Orange Book — a narrow definition that may exclude most current products pending market exclusivity status. The bill text also applies specifically to Part D, not Part B, limiting the addressable market. Losers are the Part D plan sponsors (UNH, CVS, HUM, CI) who lose utilization management tools and face higher drug spend without offset.

REAL MARKET DATA ANALYSIS: Over the past 30 days, major managed care stocks have rallied significantly: UNH +34.99% (current $365.28), HUM +40.44% ($243.52), CVS +15.57% ($83.00), CI +5.87% ($282.42). This broad sector rally is unrelated to a dormant bill introduced three months ago. The 30-day gains correlate with better-than-expected Medicare Advantage Star ratings, lower-than-expected medical cost trends reported in Q1 2026 earnings, and broader market rotation into value/healthcare. The bill has less than 1% probability of passage in its current form in 2026 given no committee action and no offsetting funding mechanism.

TIMELINE: The bill has stalled. To advance, it would need committee markup in both Energy & Commerce and Ways & Means, a House floor vote, Senate Finance Committee consideration, a Senate floor vote, and presidential signature. The 119th Congress runs through January 2027, but with zero legislative velocity since introduction, passage in this Congress is unlikely. The effective date of January 1, 2026 has already passed — if enacted now, the effective date would need to be amended, further complicating progress.